CIK 0001651308 · Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981209416
- Phone
- 41-616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-14 | OYLER JOHN Chief Executive Officer | Option exercise · Share Option (Right to Buy) 10b5-1 | −1,264,666 | 0 | ||
| 2026-07-14 | OYLER JOHN Chief Executive Officer | Option exercise · Share Option (Right to Buy) 10b5-1 | −472,134 | 462,866 | ||
| 2026-07-13 | OYLER JOHN Chief Executive Officer | Option exercise 10b5-1 | +48,520 | $36.90 | $1.8M | 48,520 |
| 2026-07-13 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −798 | $301.94 | $241K | 47,722 |
| 2026-07-13 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −4,584 | $302.79 | $1.4M | 43,138 |
| 2026-07-13 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −26,294 | $303.83 | $8.0M | 16,844 |
| 2026-07-13 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −8,438 | $304.68 | $2.6M | 8,406 |
| 2026-07-13 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −846 | $305.57 | $259K | 7,560 |
| 2026-07-13 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −7,240 | $306.82 | $2.2M | 320 |
| 2026-07-13 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −320 | $307.41 | $98K | 0 |
| 2026-07-13 | OYLER JOHN Chief Executive Officer | Option exercise · Share Option (Right to Buy) 10b5-1 | −630,760 | 1,264,666 | ||
| 2026-07-10 | OYLER JOHN Chief Executive Officer | Option exercise 10b5-1 | +11,698 | $36.90 | $432K | 11,698 |
| 2026-07-10 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −1,493 | $296.07 | $442K | 10,205 |
| 2026-07-10 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −1,314 | $297.23 | $391K | 8,891 |
| 2026-07-10 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −3,074 | $298.35 | $917K | 5,817 |
| 2026-07-10 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −5,143 | $298.94 | $1.5M | 674 |
| 2026-07-10 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −370 | $300.12 | $111K | 304 |
| 2026-07-10 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −150 | $301.18 | $45K | 154 |
| 2026-07-10 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −136 | $302.19 | $41K | 18 |
| 2026-07-10 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −18 | $303.03 | $5K | 0 |
Page 9 of 71 · 1,406 trades